Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A multicenter, randomized, placebo-controlled, parallel-arm study of CSL312 in hereditary angioedema
2018-000605-24Phase 2Completed
- Sponsor
- CSL Behring
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hereditary angioedema (HAE) comparing CSL312 with Placebo (2 arms). Primary endpoint: Time normalized number of HAE attacks. Started Jun 2018; status: completed.
02
Drugs
garadacimab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2018-000605-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000605-24.